FDA Grants Priority Review for AstraZeneca's Gastric Cancer Therapy Sonesitatug Vedotin
AstraZeneca (AZN) has received a priority review from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application for sonesitatug vedotin (Sone-Ve). The therapy is being developed as an antibody-drug conjugate intended to treat gastric cancer. A priority review designation accelerates the FDA's evaluation process, potentially leading to a faster market entry if approved. This development marks a significant step in AstraZeneca's oncology pipeline and its efforts to expand treatment options for gastric cancer patients.

Tickers: $AZN
Topics: biologics license application gastric cancer therapy priority review